NYSE American - Delayed Quote USD

Stereotaxis, Inc. (STXS)

Compare

2.0800

-0.0300

(-1.42%)

At close: January 13 at 4:00:00 PM EST

2.0500

-0.03

(-1.44%)

Pre-Market: 6:58:40 AM EST

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology

ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis. Oulu University Hospital has significant experience pioneering the use of robotic technologies for the treatment of heart arrhyt

GlobeNewswire 2 minutes ago

STXS
-1.42%
Why Stereotaxis (STXS) Is Among the Cheap Robotics Stocks to Invest In Now?

We recently compiled a list of the 10 Cheap Robotics Stocks to Invest In Now. In this article, we are going to take a look at where Stereotaxis, Inc. (NYSE:STXS) stands against other robotics stocks to buy now. Global Robotics Market Outlook The robotics industry, which has grown modestly over the past few years, has […]

Insider Monkey 23 hours ago

STXS
-1.42%
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot

Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.

Zacks 28 days ago

STXS
-1.42%
CAH
NMPA approves Stereotaxis and MicroPort’s ablation catheter

The catheter operates in unison with Stereotaxis' robotic systems, notably the Genesis RMN.

Medical Device Network last month

STXS
-1.42%
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China’s NMPA

ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced that the Magbot™ Magnetic Navigation Ablation Catheter has received regulatory approval from China’s National Medical Products Administration (NMPA). The Magbot™ Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The cath

GlobeNewswire last month

STXS
-1.42%
Stereotaxis’ GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems

ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis’ latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems’ booth at the Radiology Society of North America’s (RSNA) 2024 Annual Meeting taking place December 1-5 in Chicago, IL. RSNA is the premier annual radiology forum in the world, with over 50,000 attendees from over 15

GlobeNewswire last month

STXS
-1.42%
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System

Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.

Zacks last month

STXS
-1.42%
ANGO
+1.30%
GMED
Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference

ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 36th Annual Healthcare Conference. Mr. Fischel will deliver a formal presentation on Stereotaxis’ technology and growth strategy on Thursday, December 5, 2024, at 2:00 pm ET. Mr. Fischel will be available for one-on-one meetings that same

GlobeNewswire last month

STXS
-1.42%
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced regulatory approval of the Genesis RMN® System by China’s National Medical Products Administration (NMPA). This approval is a significant milestone, making available the latest advances in minimally-invasive robotic technology to physicians and patients in China. MicroPort EP is initiating full commercial launch of Genesis thr

GlobeNewswire last month

STXS
-1.42%
Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System. “We are excited to be at the forefront of technology and patient care by introducing the new Genesis System at Hospital da Luz,” said Prof. P

GlobeNewswire last month

STXS
-1.42%
Stereotaxis Reports Strong Q3 Growth in Robotics

Stereotaxis ( (STXS) ) has released its Q3 earnings. Here is a breakdown of the information Stereotaxis presented to its investors. Stereotaxis, a leader in surgical robotics for minimally invasive endovascular interventions, provides cutting-edge robotic systems that enhance patient care and operational efficiency in the medical field. In its third quarter of 2024, Stereotaxis reported a strong revenue growth of 18% year-over-year, driven primarily by the increasing demand for its Genesis robot

TipRanks 2 months ago

STXS
-1.42%
Q3 2024 Stereotaxis Inc Earnings Call

Q3 2024 Stereotaxis Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

STXS
-1.42%
Stereotaxis Inc. (STXS) Reports Q3 Loss, Tops Revenue Estimates

Stereotaxis (STXS) delivered earnings and revenue surprises of -60% and 35.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

STXS
-1.42%
Stereotaxis Reports 2024 Third Quarter Financial Results

ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. “The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline,” said David Fischel, Chairman and CEO. “We are making broad, me

GlobeNewswire 2 months ago

STXS
-1.42%
Delcath Systems, Inc. (DCTH) Reports Q3 Loss

Delcath Systems (DCTH) delivered earnings and revenue surprises of 76.92% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

STXS
-1.42%
Avinger (AVGR) Reports Q3 Loss, Tops Revenue Estimates

Avinger (AVGR) delivered earnings and revenue surprises of 10.34% and 3.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

AVGR

STXS
-1.42%
Kansas health centre adopts Stereotaxis’ endovascular robot

The Genesis endovascular robot system has been used to treat patients with arrhythmias at the University of Kansas health system.

Medical Device Network 2 months ago

STXS
-1.42%
University of Kansas Medical Center Enhances Robotic Heart Care Program with Genesis Robotic Technology

ST. LOUIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the University of Kansas Health System have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis. The health system is renowned for diagnosing and treating complex heart conditions. The Genesis System is the latest advancem

GlobeNewswire 2 months ago

STXS
-1.42%
Stereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024

ST. LOUIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 third quarter on Monday, November 11, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What: Stereotaxis third quarter 2024

GlobeNewswire 2 months ago

STXS
-1.42%
Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation’s Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The

GlobeNewswire 2 months ago

STXS
-1.42%

Performance Overview

Return	STXS	S&P 500
YTD	-10.34%	-1.20%
1-Year	+11.83%	+22.00%
3-Year	-64.20%	+23.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Stereotaxis, Inc. (STXS)

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology

Why Stereotaxis (STXS) Is Among the Cheap Robotics Stocks to Invest In Now?

STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot

NMPA approves Stereotaxis and MicroPort’s ablation catheter

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China’s NMPA

Stereotaxis’ GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems

STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System

Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference

Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

Stereotaxis Reports Strong Q3 Growth in Robotics

Q3 2024 Stereotaxis Inc Earnings Call

Stereotaxis Inc. (STXS) Reports Q3 Loss, Tops Revenue Estimates

Stereotaxis Reports 2024 Third Quarter Financial Results

Delcath Systems, Inc. (DCTH) Reports Q3 Loss

Avinger (AVGR) Reports Q3 Loss, Tops Revenue Estimates

Kansas health centre adopts Stereotaxis’ endovascular robot

University of Kansas Medical Center Enhances Robotic Heart Care Program with Genesis Robotic Technology

Stereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

Performance Overview